Compare · JNJ vs KTTA
JNJ vs KTTA
Side-by-side comparison of Johnson & Johnson (JNJ) and Pasithea Therapeutics Corp. (KTTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and KTTA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $641.88B, about 35573.2x KTTA ($18.0M).
- Over the past year, JNJ is up 50.5% and KTTA is down 32.3% - JNJ leads by 82.9 points.
- JNJ has been more active in the news (12 items in the past 4 weeks vs 3 for KTTA).
- JNJ has more recent analyst coverage (25 ratings vs 1 for KTTA).
- Company
- Johnson & Johnson
- Pasithea Therapeutics Corp.
- Price
- $268.71+0.88%
- $0.54-1.33%
- Market cap
- $641.88B
- $18.0M
- 1M return
- +3.05%
- +10.70%
- 1Y return
- +50.54%
- -32.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 3
- Recent ratings
- 25
- 1
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director Hewson Marillyn A
- Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target
- New insider Cavanaugh Thomas claimed ownership of 499 shares (SEC Form 3)
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Latest KTTA
- Pasithea Therapeutics Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
- Pasithea Therapeutics Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Pasithea Therapeutics Corp.
- SEC Form DEF 14A filed by Pasithea Therapeutics Corp.
- Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.
- SEC Form PRE 14A filed by Pasithea Therapeutics Corp.
- Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
- Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
- Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion